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Abstract 
To improve a previously constructed broadly neutralizing hepatitis B virus (HBV)-specific 
preS1 humanized antibody (HzKR127), we further humanized it through specificity-
determining residue (SDR) grafting. Moreover, we improved affinity by mutating two 
residues in heavy-chain complementarity-determining regions (CDR), on the basis of the 
crystal structure of the antigen–antibody complex. HzKR127-3.2 exhibited 2.5-fold higher 
affinity and enhanced virus-neutralizing activity compared to the original KR127 antibody 
and showed less immunogenic potential than HzKR127. Enhanced virus-neutralizing activity 
was achieved by the increased association rate, providing insights into engineering potent 
antibody therapeutics for HBV immunoprophylaxis. HzKR127-3.2 may be a good candidate 
for HBV immunoprophylaxis. 
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1. Introduction 
Over the last three decades, monoclonal antibodies (mAbs) have emerged as powerful 
human therapeutics due to advances in antibody engineering technologies [1]. Nonhuman 
antibodies induce an immune response in humans, which limits their therapeutic use [2]. To 
overcome this problem, humanized antibodies have been constructed by grafting the 
complementarity-determining regions (CDRs) of murine mAbs onto human framework 
regions (FRs), which is commonly referred to as CDR grafting [3]. Simple grafting of CDRs, 
however, often decreases affinity, because some FR residues directly contact the antigen or 
support conformation of the CDR loops [4, 5]. Therefore, humanized antibodies are usually 
constructed by CDR grafting while retaining those mouse FR residues that influence antigen-
binding activity [6, 7]. These humanized antibodies are generally less immunogenic in 
patients than chimeric antibodies that are composed of mouse variable domains and human 
constant domains; however, they may still be immunogenic since the CDRs are not human [8, 
9]. Therefore, to minimize the immunogenicity of humanized antibodies, only the mouse 
CDR residues that influence antigen binding (i.e., specificity-determining residues, or SDRs) 
are retained, while those that are not involved in antigen binding are replaced by human 
counterparts [10-13]. SDR-grafted humanized antibodies exhibit less immunogenic potential 
than CDR-grafted humanized antibodies. 
HBV is a worldwide public health problem that affects 240 million chronic carriers, who 
have a high risk of developing hepatocellular carcinoma [14]. The HBV envelope contains 
three related surface glycoproteins called the large (L), middle (M), and small (S) proteins. 
These proteins are the product of a single open reading frame that is divided into preS1, 
preS2, and S regions [15]. The S protein is encoded by the S region; the M protein contains 
the preS2 and S antigens; and the L protein contains the preS1, preS2, and S antigens. The 
three antigens have been shown to elicit virus-neutralizing antibodies [16-20]. In particular, 
the preS1(amino acids 2–48, ayw subtype) of the L protein and the common “a” determinant 
of the S antigen have been shown to play an essential role in viral infectivity [21-27]. 
Recently a cellular receptor for the pre-S1 sequence was identified as sodium taurocholate 
transporter (NTCP) [28], while heparin sulfate proteoglycan (HSPG) was recognized as a 
binding partner for the “a” determinant [29]. For immunoprophylaxis of HBV infection, 
hepatitis B immune globulin (HBIG) prepared from pooled human anti-HBsAg plasma is 
administered to infants born of HBsAg-HBeAg–positive mothers, to susceptible individuals 
with acute exposure to infectious HBV-containing material, and to orthotopic liver transplant 
  
patients with chronic HBV-related liver disease [30-32]. However, the currently available 
HBIG is not an ideal source of antibody due to its limited availability and low specific 
activity. Virus-neutralizing mAbs against the preS1 and S antigens would be an effective 
alternative for immunoprophylaxis of HBV infection. 
We previously generated a murine mAb (KR127) that recognizes amino acids 37–45 
(NSNNPDWDF) of the preS1 of adr subtype, corresponding to aa 26–34 of ayw subtype, and 
subsequently constructed a humanized antibody (HzKR127) by CDR grafting. HzKR127 
retained the same epitope specificity and affinity as KR127 and exhibited HBV-neutralizing 
activity in chimpanzees [33-35]. In addition, we determined the crystal structure of the 
HzKR127 antigen-binding fragment (Fab) and its complex with the epitope to understand the 
structural mechanisms of the antigen–antibody interaction [36]. 
In the present study, based on the structural information, we further humanized HzKR127 
by SDR grafting and also improved its affinity by mutating two heavy-chain CDR residues. 
The resulting humanized antibody (HzKR127-3.2) exhibited higher HBV-neutralizing 
activity than KR127 and lower immunogenic potential than HzKR127. The enhanced virus-
neutralizing activity was achieved by an increase in the association rate. This information will 
be useful for the design and development of potent antibody therapeutics against HBV, and 
this advanced humanized antibody may be a good candidate for immunoprophylaxis of HBV 
infection. 
  
2. Materials and methods 
2.1. Cell culture 
HEK293T, ACHN, B16F1, and SCK-L1 [37] cells were grown in DMEM (Invitrogen) 
supplemented with 10% FBS. CHO-DG44 cells were grown in DMEM/F12 (Invitrogen) with 
supplements as described previously [35]. HepaRG cells were cultured and differentiated as 
previously described [24] and maintained after seeding into 96-well plates in William’s E 
medium (Gibco Life technologies) supplemented with 5% fetal calf serum, 2% DMSO, 5 
mg/L insulin, 5 × 10−6 M hydrocortisone, 5 µg/L sodium selenite, 20,000 UI/L penicillin, and 
20 mg/L streptomycin. All cells were cultured in 5% CO2 in a 37°C humidified incubator. 
 
2.2. Construction, expression, and purification of humanized antibodies 
Humanized VH and VL genes were synthesized by GeneArt (Germany) and sequentially 
subcloned into the EcoRI-ApaI and HindIII-BsiWI sites, respectively, of pdCMV-dhfrC-
  
cA10A3 containing human C1 and C. The resulting expression plasmids were introduced 
into HEK293T cells using Lipofectamine (Invitrogen). The culture supernatant was subjected 
to affinity chromatography on a protein A–sepharose column (Millipore), and the protein 
concentration was determined with a NanoDrop (Thermo Scientific) based on the molar 
extinction coefficient. The integrity of the purified protein was analyzed by SDS-PAGE. 
 
2.3. Affinity determination  
Competition ELISA was performed as described previously [38]. Briefly, a solution 
containing 5–10 ng of each antibody and various concentrations (10−10–10−6 M) of GST-
preS1 (amino acids 1–56) as a competing antigen were preincubated at 37°C for 3 h. The 
mixtures were then added to each well, which had been coated with 100 ng of GST-preS1. 
Bound antibody was detected by indirect ELISA.  
For affinity determination by Octet Red, anti-human Fc–coated biosensor tips (ForteBio, 
18-0015) were activated in PBS with 0.1% w/v bovine serum albumin (0.1% PBA) for 20 
min by agitating 96-well microtiter plates (Greiner bio-one, 655209) at 1000 rpm and then 
saturated with 2 g/mL antibody for 10 min. This typically resulted in capture levels of 1 nm. 
GST-preS1 was prepared as a 2-fold serial dilution (6.25, 12.5, 25, 50, and 100 nM) in 0.1% 
PBA and separately incubated with the antibody bound on the tips. Association and 
dissociation rates were measured for 15 and 30 min, respectively. All measurements were 
corrected for baseline drift by subtracting a control sensor exposed to running buffer only. 
Operating temperature was maintained at 30°C. Data were analyzed using a 1:1 interaction 
model (fitting global, Rmax unlinked by sensor) with ForteBio data analysis software 7.0. 
 
2.4. Western blot analysis 
GST-preS1 (amino acids 1–56) and each of the alanine replacement mutants of the preS1 
(amino acids 37–47) were expressed in E. coli DH5 cells as described previously [38]. 
Protein extracts were subjected to 12% SDS-PAGE and western blot analysis with KR127 or 
humanized KR127 antibody (1 g/ml), followed by anti-mouse or human IgG (Fc-specific)–
HRP conjugate (1:5000 v/v, Thermo Scientific). 
 
2.5. Flow cytometric analysis 
Cells were incubated with 1 g of antibody in 100 l of PBA for 60 min at 4°C. After 
washing three times with PBA, the cells were incubated with a fluorescein isothiocyanate–
  
conjugated anti-hFc antibody (BD Pharmingen) for 30 min at 4°C. Propidium iodide–
negative cells were analyzed for antibody binding using FACSCalibur (Becton Dickinson).  
 
2.6. In vitro HBV infection and neutralization assays 
In vitro HBV infection and neutralization assays were carried out using differentiated 
HepaRG cells and adr or ayw subtype of HBV particles. The ayw viral particles were 
produced by transient transfection of HepG2 cells [39] with plasmid (pHBVEcoR1-) 
containing an overlength HBV genome originally described in Gripon et al. [40], and 
supernatants from the transfected cells were concentrated fifty-fold by PEG precipitation as 
previously described [23]. The genomic sequence of the ayw subtype corresponds to the 
sequence (genebank accession number V01460.1) published by Galibert et al. [41], 
corresponding to genotype D by online genotyping analysis [42]. The adr particles were 
produced and concentrated by the same procedures using the pHBV 5.2 [43] containing the 
preS1 sequence [44] that was identified as genotype C by the online genotyping analysis.  
For in vitro HBV infection, HepaRG cells were seeded at a density of 6 × 104 cells per well 
(containing 100 µl of culture medium) and were infected 6 days later with the adr or ayw 
viral particles (about 6 x 106 viral genomic equivalent). HBV infection was also performed in 
the presence of 4% PEG 8000 and a five-fold diluted inoculum. PEG was added during the 
infection process, which allows a great enhancement of viral infectivity without 
compromising the specificity of the infection process as previously described [45]. To 
evaluate binding of antibody to the viral particles present in the HBV inocula, ELISA plates 
were coated with either KR127 or HzKR127-3.2 (1 µg/ml) in a carbonate buffer overnight at 
room temperature. After saturation with 5% fetal calf serum for 2 h at room temperature, 
serially diluted HBV inocula were added and incubated for 4 h at room temperature. The 
bound viral particles were then detected with an anti-HBs antibody conjugated with 
peroxidase from a HBs detection kit (Bio-Rad).  
For the neutralization assay, the adr or ayw viral particles (5 µl) were preincubated with 5 
µl of antibody at the indicated concentrations at room temperature for 30 min and then 
incubated with cultured HepaRG cells covered with 100 µl of the culture medium for 24 
hours in the absence or presence of 4% PEG 8000. The infected cells were washed with the 
medium and further incubated for 10 days, with the medium changed every 2 days. On day 
10 postinfection, the culture supernatant was diluted in order to remain in the quantitative 
  
range of the assay and the HBsAg concentration was determined with an ELISA kit (Bio-
Rad). 
 
3. Results 
3.1. Construction of humanized antibody HzKR127-3 by SDR grafting 
We previously constructed an anti-preS1 humanized antibody (HzKR127) from the murine 
mAb KR127 by CDR grafting. In HzKR127, the CDRs of mouse VH and VL were grafted 
into human germline segments DP7-JH4 and DPK12-JK4, respectively, while eleven FR 
residues in the mouse VH and five FR residues in the mouse VL that were thought to 
influence the CDR loops or to stabilize the structure of the variable regions were retained 
[35]. The amino acid sequences of the VH and VL of KR127 and HzKR127 are shown in 
Figure 1. In this study, we further humanized HzKR127 by SDR grafting and increased its 
affinity by site-directed mutagenesis. 
For SDR grafting, mouse residues that are buried and/or not involved in antigen binding 
are replaced by human counterparts, based on the previously determined three-dimensional 
structure of the antigen–antibody complex [36].For the VH, nine mouse FR residues (Val12, 
Ala28, Ser30, Ile48, Lys66, Ala67, Leu69, Ala78, and Phe91) were replaced by human 
residues, while two mouse FR3 residues (Ala71 and Lys73) that are involved in the 
interaction with HCDR2 loop were retained. Ala71 is in hydrophobic interaction with Ile51 
and Pro53, and Lys 73 is in hydrogen bonding with Gly54 (Fig. 2A). For the VL, three mouse 
FR residues (Leu3, Ser43, and Lys45) were replaced by human residues, while two mouse 
FR2 residues (Leu36 and Arg46) were retained. Leu36 forms a tight interaction with Trp103 
of VH in the bottom of the antigen-binding pocket and is close to the Glu98 side chain of the 
HCDR3 loop (Fig. 2B). Thus, mutation of Leu36 to Tyr is likely to disturb the conformation 
of the antigen-binding pocket and prohibit optimal binding to the antigen. Residue Arg46 
forms a salt bridge with Asp97 in HCDR3, which stabilizes the conformation of HCDR3 in 
the free structure (Fig. 3A). In addition to the FR residues, two LCDR2 residues (Lys53 and 
Leu54) were replaced by human residues because they are not involved in antigen binding 
(Fig. 2C). 
The designed humanized VH and VL sequences were synthesized and combined with 
human C1 and C, respectively, to construct expression plasmid pdCMV-dhfrC-HzKR127-3. 
This plasmid DNA was introduced into HEK293T cells, and the resulting humanized 
antibody (HzKR127-3) was purified from the culture supernatant. Affinity determination by 
  
competition ELISA indicated that the affinity of HzKR127-3 for GST-preS1 was slightly 
lower than that of the original KR127 antibody (Supplemental Fig. S1). Affinity 
determination by Octet Red indicated that HzKR127-3 had approximately 3-fold lower 
affinity (KD) compared to KR127; this decrease was due mostly to an increase in the 
dissociation rate (Supplemental Fig. S2A and S2B and Table 1). 
 
3.2. Affinity maturation of HzKR127-3 
In our previous structural study, a comparison of the structures of free HzKR127 Fab and 
its complex with the preS1 epitope revealed that the HCDR3 loop undergoes the most 
noticeable conformational change between the free and complex structures, illustrating a lid-
opening mechanism for antigen binding [36]. As shown in Figure 3A, the Asp97 residue is 
not involved in a direct interaction with the preS1 antigen; rather, it forms a salt bridge with 
Arg46 in the light chain FR2, which stabilizes closing of the HCDR3 lid in the free structure. 
However, upon antigen binding, the HCDR3 loop lid is opened and an antigen-binding 
pocket is thereby created, leading to tight locking in of the peptide (Fig. 3B). Residue Asp97 
is located at the apex of the HCDR3 lid and undergoes the largest movement, with a 9.6 Å 
shift in the main chain upon lid opening (Supplemental Fig. S3). Alanine mutation of the 
Asp97 would disrupt the salt bridge, making the HCDR3 loop more flexible. This could 
facilitate the structural transition from the closed to the open state, thus leading to an increase 
in affinity. We therefore substituted an alanine for Asp97 of HzKR127-3. The resulting 
antibody (HzKR127-3.1) was transiently expressed in HEK293T cells, purified, and 
subjected to affinity determination by competition ELISA followed by Octet Red. The 
affinity of HzKR127-3.1 (8.13 × 10−10 M) was 4.9-fold higher than that of HzKR127-3 (3.97 
× 10−9 M), and the increase in affinity was achieved mostly by a decrease in the dissociation 
rate (Supplemental Fig. S1 and S2C and Table 1). 
In an attempt to further increase the affinity of HzKR127-3.1, Asn58 in HCDR2 of 
HzKR127-3.1 was mutated to alanine and subjected to competition ELISA, which showed an 
increase in affinity (data not shown). This indicates that Asn58 is not optimal for antigen 
binding. We speculated that the replacement of Asn58 by alanine, which has a smaller side 
chain, would give the preS1 epitope easier access to the antigen-binding pocket, which could 
result in a faster association rate (Fig. 2D). Therefore, Asn58 was replaced by the human 
counterpart (Ser58) as a first choice. The resulting humanized antibody (HzKR127-3.2) was 
transiently expressed, purified, and subjected to affinity determination. The affinity of 
  
HzKR127-3.2 (4.93 × 10−10 M) was 1.6-fold higher than that of HzKR127-3.1, and the 
increased affinity was achieved mostly by an increase in the association rate (Supplemental 
Fig. S1 and S2D and Table 1).  
 
3.3. Analysis of potential immunogenicity of HzKR127-3.2 
The VH and VL sequences of HzKR127 and HzKR127-3.2 were analyzed with ProPred 
[46] to identify potential T cell epitopes that bind to MHC II molecules (HLA-DR). This is 
based on the fact that the peptide–MHC II complexes are recognized by helper T cells and 
trigger the activation and differentiation of helper T cells to stimulate the immune response. 
As summarized in Table 2, potential T cell epitopes detected at the junction between HCDR2 
and FR3 (HCDR2/FR3) or in the light chain FR2 of HzKR127 were eliminated in HzKR127-
3.2, while those detected at the junction between light chain FR2 and LCDR2 (FR2/LCDR2) 
were greatly reduced. 
 
3.4. Specificity of HzKR127-3.2 
To confirm the antigen-binding specificity of HzKR127-3.2, a series of GST-preS1 (amino 
acids 1–56) proteins that individually carry an alanine replacement mutation at each position 
in the preS1 epitope were expressed in E. coli and subjected to western blot analysis with 
KR127 or HzKR127-3.2. As shown in Figure 4A, HzKR127-3.2 exhibited the same epitope 
specificity as that of KR127. 
In addition, to determine whether HzKR127-3.2 does not exhibit off-target activity, flow 
cytometric analysis was performed. To prepare preS1-expressing cells (293T-S1-L1) as a 
positive control, preS1 (amino acids 37–47) was fused to the N-terminus of the integral 
membrane protein L1 cell adhesion molecule (L1CAM). The fusion protein was then 
transiently expressed in HEK293T cells. HzKR127-3.2 bound to the surface of the 293T-S1-
L1 cells but did not bind to preS1-negative cells such as HEK293T, L1CAM-overexpressing 
human cholangiocarcinoma (SCK-L1), human renal carcinoma (ACHN), mouse melanoma 
(B16F1), and Chinese hamster ovary (CHO) cells (Fig. 4B). 
 
3.5. Evaluation of HBV-neutralizing activity of HzKR127-3.2 
Because HzKR127-3.2 exhibited higher affinity for the preS1 antigen than KR127, we 
compared their virus-neutralizing activities by in vitro HBV-neutralization assay. To begin 
with, we confirmed binding of the antibodies to the viral particles. As shown in Figure 5A, 
  
the antibodies bound to the ayw and adr particles in a dose-dependent manner, and 
HzKR127-3.2 bound more efficiently compared to KR127. Next, HepaRG cells were infected 
with either the adr or ayw subtype of HBV particles, which had been preincubated with 
different concentrations (0.2–200 g/ml) of each antibody. The infected cells were then 
cultured for 10 days, and the growth medium was changed every 2 days. On day 10 
postinfection, HBsAg secretion by the infected cells was measured by ELISA. As shown in 
Figure 5B and 5C, the HBsAg secretion rate gradually decreased with increasing antibody 
concentration, demonstrating the specificity of the neutralization assay, and HzKR127-3.2 
exhibited enhanced virus-neutralizing activity against both adr and ayw subtypes compared 
to KR127. 
We also performed the HBV infection and neutralization assay in the presence of 4% PEG 
8000. The presence of PEG increases the infectivity and thus allowed to use five-fold diluted 
inoculum without compromising infectivity [45]. Because this assay has a higher ratio of 
antibody molecules to viral particles compared to the assay in the absence of PEG, it was 
expected to improve the neutralization activity of the antibodies, although it is not under 
physiological conditions. Indeed the infection level was higher since HBsAg production 
reached 100 ng/ml, and an almost complete neutralization was observed with the highest 
antibody dose, while HzKR127-3.2 neutralized the viral particles more efficiently than 
KR127 (Supplemental Fig. S4).  
 
4. Discussion 
We had previously constructed the CDR-grafted humanized antibody HzKR127; the 
epitope specificity and affinity of HzKR127 are the same as those of the original murine mAb, 
KR127. HzKR127 virus-neutralizing activity was confirmed in chimpanzees. Subsequently, 
the crystal structures of HzKR127 Fab and its complex with the epitope revealed that 
HzKR127 exerts a lid-opening mechanism for antigen binding, one of the largest 
conformational changes in antigen–antibody recognition. In the present study, we 
successfully optimized HzKR127 through SDR grafting and affinity maturation by rational 
design based on the antigen–antibody complex structure. A total of 15 (12 in FR, one in 
HCDR2, and two in LCDR2) mouse residues in HzKR127 were replaced by human residues, 
and Asp97 in HCDR3 was replaced by alanine. The resulting humanized antibody 
(HzKR127-3.2) exhibited 2.5-fold higher affinity for the preS1 antigen and enhanced virus-
neutralizing activity against both adr and ayw subtypes of HBV compared to KR127. 
  
Moreover, it retained the same epitope specificity as that of KR127 and did not show any off-
target activity, as assessed by flow cytometric analysis. In addition, T epitope analysis 
suggested that HzKR127-3.2 may be less immunogenic in humans than HzKR127. 
Considering that HzKR127 exhibited virus-neutralizing activity in chimpanzees, HzKR127-
3.2 might exhibit higher in vivo virus-neutralizing activity than HzKR127 and thus may be 
more effective in the immunoprophylaxis of HBV infection. HzKR127-3.2 may be 
particularly useful for repeated administration to humans because of its minimized 
immunogenic potential. 
KR127 and HzKR127-3.2 target amino acids 37-45 from the L protein of adr subtype, 
corresponding to amino acids 26-34 of ayw subtype. This epitope lies in preS1 region of the 
L protein which is involved in HBV infectivity, since the target of the peptide(amino acids 2-
47, ayw subtype) was identified as NTCP and shown to be a functional receptor for HBV 
entry [28]. Therefore, our antibodies target a region crucial for HBV infectivity and thus were 
expected to block entry. However, Bremer et al. reported that antibodies against preS1(1-21) 
of ayw subtypes reacted well with non-myristoylated preS1 peptides but only weakly with 
myristoylated preS1 peptides and did not neutralize the infectivity of HBV, whereas 
antibodies to neighboring sequences neutralized very well [47]. The data suggest that 
antibodies to preS1(22-47) of ayw subtypes are likely to bind well to HBV and neutralize 
viral infectivity. Indeed, we observed that HzKR127-3.2 recognizing preS1(37-45) of adr 
subtypes bound to the viral particles of both ayw and adr subtypes and neutralized them 
efficiently. Analysis of antigen-antibody interaction of HzKR127-3.2 indicated that seven 
residues in the epitope sequence, except Ser38 and Asn39, are essential for antibody binding 
(Figure 4). Among the essential residues, five residues (Asn37, Pro41, Asp42, Trp43, and 
Asp44) are highly conserved among genotypes [28], while the other two residues (Asn40 and 
Phe45) are infrequently changed to serine and leucine or histidine, respectively in some 
genotypes. Neutralization efficiency of HzKR127-3.2 against these genotypes remains to be 
determined.  
Regarding the correlation between kinetic parameters and virus-neutralizing potency, 
studies with mAbs against respiratory syncytial virus (RSV) F protein have shown that a 
direct relationship exists between the association rate and RSV-neutralizing activity [48-50],  
while studies with other viral pathogens, such as human immunodeficiency virus or rotavirus, 
have shown that virus-neutralizing activity can be determined predominantly by the 
dissociation rate [51, 52]. In case of HBV-neutralizing antibody, a recent study showed no 
  
correlation between the affinity of anti-S monoclonal antibodies and their ability to neutralize 
HBV infection [53].  In this study, HzKR127-3.2 exhibited 2.5-fold higher affinity for the 
preS1 and enhanced in vitro virus-neutralizing activity against both adr and ayw subtypes of 
HBV compared to KR127, while the association rate was 2.3-fold faster and the dissociation 
rate was slightly slower. These data indicate that the enhanced virus-neutralizing activity was 
achieved by an increased association rate, which suggests that the association rate of anti-
preS1 antibodies may play a predominant role in HBV neutralization. To the best of our 
knowledge, this is the first study to show a direct relationship between the association rate 
and neutralizing potency in antibody-mediated HBV neutralization. Our findings may 
provide insights that will help to facilitate the engineering of potent antibody therapeutics for 
HBV immunoprophylaxis. 
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Figure legends 
Fig. 1. Amino acid sequences of VH (A) and VL (B) of murine antibody KR127 and 
humanized antibodies (HzKR127, HzKR127-3, HzKR127-3.1 and HzKR127-3.2). DP7 and 
DPK12 are the human Ig VH and V germ-line segments, respectively. The dashes indicate 
identical amino acid residues. 
 
Fig. 2. Crystal structure of the HzKR127 Fab–preS1 complex. (A) Interaction between the 
VH FR3 residue (Ala71H or Lys73H) and HCDR2 (H2) loop. (B) Interaction between the 
VL FR2 residue (Leu36L) and Trp103H in FR4. (C) Location of the LCDR2 residues 
(Leu54L and Lys53L). (D) Location of Asn58H in HCDR2. The VH and VL are shown in 
blue and in pink, respectively. The CDR loops and preS1 peptide are colored yellow and 
green, respectively.  
 
Fig. 3. Hydrogen bonds between the HCDR3 lid (yellow) and neighboring residues in the 
free (A) and preS1-bound (B) HzKR127 Fab. The residues involved in the hydrogen bonds 
are labeled, and the hydrogen bonds are indicated as dotted lines. The preS1 peptide is shown 
in green. The light and heavy chains are colored pink and blue, respectively.  
 
Fig. 4. Validation of epitope specificity (A) and off-target activity (B) of HzKR127-3.2. (A) 
GST-preS1 (amino acids 1–56) protein (WT) and a series of alanine replacement mutants 
were expressed in E. coli and subjected to 12% SDS-PAGE (bottom) followed by western 
blot analysis with KR127, HzKR127-3.1, or HzKR127-3.2 (Top). The protein band 
corresponding to the GST-preS1 is marked. (B) HzKR127-3.2 was subjected to flow 
cytometric analysis using preS1-expressing HEK293T cells (293T-S1-L1) and preS1-
negative cells (HEK293T, SCK-L1, ACHN, B16F1, and CHO). 
 
Fig. 5. In vitro HBV binding (A) and neutralization (B and C) assays of HzKR127-3.2 
against ayw or adr subtypes of HBV. 
 
Supplemental Fig. S1. Affinity determination of antibodies by competition ELISA.  
 
Supplemental Fig. S2. Affinity determination of antibodies using Octet Red.  
 
  
Supplemental Fig. S3. Crystal structure of the HzKR127 Fab–preS1 complex showing 
HCDR3 lid opening. The free and bound structures of HzKR127 Fab are superimposed. The 
CDRS of free and bound forms are shown in pink and in blue, respectively. 
 
Supplemental Fig. S4. In vitro HBV neutralization assays of HzKR127-3.2 in the presence of 
4% PEG against ayw (A) or adr (B) subtype of HBV. 
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Table 1. Affinity determination of murine and humanized antibodies using Octet Red 
Antibody name KD (M) Kon (1/Ms) Koff (1/s) 
KR127 1.23 x 10
-9
 4.68 x 10
4
 5.74 x 10
-5
 
HzKR127-3 3.97 x 10
-9
 4.23 x 10
4
 1.68 x 10
-4
 
HzKR127-3.1 8.13 x 10
-10
 5.08 x 10
4
 4.13 x 10
-5
 
HzKR127-3.2 4.93 x 10
-10
 1.08 x 10
5
 5.32 x 10
-5
 
  
  
Table 2. Assessment of potential immunogenicity of humanized antibodies  by T-cell 
epitope analysis. Prediction of HLA-DR binding sites by ProPred analysis 
(www.imtech.res.in/raghave/proped/index.html)?
Antibody HzKR127 HzKR127-3.2 HzKR127 HzKR127-3.2 HzKR127 HzKR127-3.2 
Location HCDR2/FR3 FR2 in VL FR2/LCDR2 
Peptide  
sequence YNGKFKGKA YAQKFQGRV WLLQKPGQS WLLQKPGQP IYLVSKLDS IYLVSNRDS 
MHC 
Class II  
molecules 
that  
Bind to  
peptide 
DRB1_0801 
DRB1_0802 
DRB1_0804 
DRB1_0806 
DRB1_0813 
DRB1_0817 
DRB1_1307 
 
DRB1_0305 
DRB1_0309 
DRB1_0401 
DRB1_0426 
DRB1_0802 
DRB1_1101 
DRB1_1114 
DRB1_1120 
DRB1_1128 
DRB1_1302 
DRB1_1305 
DRB1_1307 
DRB1_1323 
DRB5_0101 
DRB5_0105 
 
DRB1_0301 
DRB1_0305 
DRB1_0306 
DRB1_0307 
DRB1_0308 
DRB1_0309 
DRB1_0311 
DRB1_0801 
DRB1_0802 
DRB1_0804 
DRB1_0806 
DRB1_0813 
DRB1_0817 
DRB1_1101 
DRB1_1102 
DRB1_1104 
DRB1_1106 
DRB1_1107 
DRB1_1114 
DRB1_1120 
DRB1_1121 
DRB1_1128 
DRB1_1301 
DRB1_1302 
DRB1_1304 
DRB1_1305 
DRB1_1307 
DRB1_1311 
DRB1_1321 
DRB1_1322 
DRB1_1323 
DRB1_1327 
DRB1_1328 
DRB1_0402 
DRB1_0404 
DRB1_0405 
DRB1_0408 
DRB1_0410 
DRB1_0423 
DRB1_1102 
DRB1_1121 
DRB1_1322 
DRB5_0101 
Total 
number 7 0 15 0 33 10 
 
 
 
  
  
Highlights 
• Anti-hepatitis B virus preS1 humanized antibody was constructed by SDR grafting. 
• SDR-grafted humanized antibody was affinity-matured by mutating two HCDR residues. 
• Affinity matured humanized antibody exhibits enhanced HBV-neutralizing activity. 
• Enhanced HBV-neutralizing activity was achieved by an increased association rate.  
 
